In laboratory animals, one of the major precipitants of relapsethat is, resumption of drug seekingis stress. For example, electric shock has been consistently shown to lead to reinstatement of heroin and cocaine seeking in rats (Shaham and Stewart, 1995;Erb et al., 1996;Shaham, 1996). This stress-induced reinstatement is blocked by the alpha-2 adrenergic receptor agonist clonidine (Erb et al., 2000;Shaham et al., 2000;Highfield et al., 2001). Because clonidine and other alpha-2 agonists prevent reinstatement for multiple drugs of abuse, they may be acting upon some final common pathway of stress-induced relapse, relevant to many or all addictions. In human-laboratory work that we discussed in last years report, we showed that clonidine reduced stress-induced cocaine craving more than cue-induced cocaine craving. To test the clinical utility and generalizability of our laboratory finding, we are conducting a clinical trial of clonidine for prevention of relapse to illicit opioid use in individuals in buprenorphine maintenance. The design of the trial is innovative. Most medication trials for substance abuse are conducted in patients who have ongoing drug use. Few studies have been designed as true relapse-prevention trials. This has been a major barrier to interpretability, because preclinical research suggests that cessation of ongoing use is very different biologically and behaviorally from prevention of relapse. In our clinical trial, abstinence initiation is facilitated with contingency management, a treatment method studied extensively in our laboratory. We are using real-time field monitoring with handheld electronic devices (a method we pioneered in this population) so we can prospectively evaluate the hypothesis that clonidines effects on relapse prevention will be through alteration of stress reactivity rather than cue reactivity in the daily environment. The trial is nearing its targeted sample size of 120. Positive results will provide an immediate treatment alternative that physicians can prescribe off-label, because clonidine is already FDA-approved and marketed. This would be a real innovation in addiction treatment: although clonidine is a familiar drug (currently used as a short-term adjuvent to opioid tapers), its use as a maintenance medication for relapse prevention would be entirely new. Our clinics experience so far, although we have not broken the blind, suggests that clonidine is well tolerated and is also not prone to misuse when prescribed for relapse prevention. Clonidine is a prototypical drug of its class in this trial;if it prevents relapse, then other alpha-2 agonists should do the same. We are also evaluating the role of stress in relapse in a large natural-history study in which real-time field monitoring of stressor exposure is combined with continuous location tracking via GPS. Preliminary analyses suggest some unexpected relationships between neighborhood environment and self-reported stress. As we collect more data, we should be able to determine how patterns of environmental-stressor exposure predict relapse. One of our goals is to supplement our ambulatory assessments with on-the-spot feedback, turning them into mobile interventions.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Institute on Drug Abuse
Zip Code
Carmona-Rivera, Carmelo; Purmalek, Monica M; Moore, Erica et al. (2017) A role for muscarinic receptors in neutrophil extracellular trap formation and levamisole-induced autoimmunity. JCI Insight 2:e89780
Kowalczyk, William J; Bertz, Jeremiah W; Moran, Landhing M et al. (2017) Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients. J Addict Med 11:454-460
Moran, Landhing M; Phillips, Karran A; Kowalczyk, William J et al. (2017) Aripiprazole for cocaine abstinence: a randomized-controlled trial with ecological momentary assessment. Behav Pharmacol 28:63-73
Preston, Kenzie L; Kowalczyk, William J; Phillips, Karran A et al. (2017) Context and craving during stressful events in the daily lives of drug-dependent patients. Psychopharmacology (Berl) 234:2631-2642
Epstein, David H; Kennedy, Ashley P; Furnari, Melody et al. (2016) Effect of the CRF1-receptor antagonist pexacerfont on stress-induced eating and food craving. Psychopharmacology (Berl) 233:3921-3932
Sheng, Yang; Filichia, Emily; Shick, Elizabeth et al. (2016) Using iPSC-derived human DA neurons from opioid-dependent subjects to study dopamine dynamics. Brain Behav 6:e00491
Heilig, Markus; Epstein, David H; Nader, Michael A et al. (2016) Time to connect: bringing social context into addiction neuroscience. Nat Rev Neurosci 17:592-9
Sheng, Yang; Filichia, Emily; Shick, Elizabeth et al. (2016) Lower Dopamine D2 Receptor Expression Levels in Human Dopaminergic Neurons Derived From Opioid-Dependent iPSCs. Am J Psychiatry 173:429-31
Preston, Kenzie L; Jobes, Michelle L; Phillips, Karran A et al. (2016) Real-time assessment of alcohol drinking and drug use in opioid-dependent polydrug users. Behav Pharmacol 27:579-84
Kiluk, Brian D; Carroll, Kathleen M; Duhig, Amy et al. (2016) Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug Alcohol Depend 158:1-7

Showing the most recent 10 out of 40 publications